Acquisition History / Servier / Muscular dystrophy business of Edgewise Therapeutics Inc.

Servier Acquires Muscular dystrophy business of Edgewise Therapeutics Inc.

Announced June 2026 — $2.65B

ServierBiopharmaceuticals2026

What happened

Edgewise Therapeutics is a Nasdaq-listed biopharma developing therapies for serious muscle disorders. French foundation-owned pharmaceutical group Servier agreed to acquire Edgewise's muscular dystrophy business for US$1.55B upfront plus up to US$1.1B in regulatory and commercial milestone payments, a total of up to US$2.65B.

Acquirer
Servier
Target
Muscular dystrophy business of Edgewise Therapeutics Inc.
Announced
June 2026
Price
$2.65B
Industry
Biopharmaceuticals
Buyer type
Strategic acquirer
Status
Announced, not yet closed

By the numbers

Servier's acquisition history
1st of 1 tracked deals
Disclosed prices
1 of 1 Servier deals
Servier's average disclosed price
$2.65B
Servier's largest disclosed deal
Muscular dystrophy business of Edgewise Therapeutics Inc. ($2.65B)
Tracked acquisitions in 2026
397 across all acquirers
Servier in Biopharmaceuticals
1 acquisition

Frequently Asked Questions About This Acquisition

When did Servier acquire Muscular dystrophy business of Edgewise Therapeutics Inc.?

Servier acquired Muscular dystrophy business of Edgewise Therapeutics Inc. on June 2026. This was Servier's 1st publicly tracked acquisition out of 1 we have on record.

How much did Servier pay for Muscular dystrophy business of Edgewise Therapeutics Inc.?

Servier paid $2.65B for Muscular dystrophy business of Edgewise Therapeutics Inc..

What does Muscular dystrophy business of Edgewise Therapeutics Inc. do?

Edgewise Therapeutics is a Nasdaq-listed biopharma developing therapies for serious muscle disorders. French foundation-owned pharmaceutical group Servier agreed to acquire Edgewise's muscular dystrophy business for US$1.55B upfront plus up to US$1.1B in regulatory and commercial milestone payments, a total of up to US$2.65B.

What other Biopharmaceuticals companies has Servier acquired?

Muscular dystrophy business of Edgewise Therapeutics Inc. is Servier's only publicly tracked acquisition in Biopharmaceuticals so far.

Read the full article →

More Biopharmaceuticals acquisitions